Eligible commercially insured patients
pay as little as
with the Aimovig® Copay Card
Encourage patients to visit aimovig.com and enroll in support programs that can help them at every stage.
A quick overview on how to self-administer Aimovig®.
A simple way for patients to get support and resources during the first 3 months.
Patients receive a text message when it’s time for a medication refill.
Patients can track their monthly migraine days by responding to a simple daily text.
Your patient’s health plan may require a prior authorization (PA) before approving Aimovig®
Use the PA Checklist to gather information to complete an Aimovig® PA request
Complete your patient’s PA through your preferred EHR platform
Obtain resources to support your clinical decision or manage PA denial
Additional tools and resources are available for your office. They may be helpful to start and support patient treatment with Aimovig®. Resources include but are not limited to Dosing Reference Guides and a Getting Started Guide.
If you have questions, please call 1-833-AIMOVIG (833-246-6844), Monday-Friday, 8:00 am-9:00 pm ET for additional support.
Aimovig® Copay Card Terms and Conditions
SUMMARY OF TERMS AND CONDITIONS
It is important that every patient read and understand the full Aimovig® (erenumab-aooe) Copay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.
As further described in the full terms and conditions, in general:
Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.
Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.
Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.
Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.
Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.
Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.
Please see Aimovig® full Prescribing Information.
Reference: 1. Data on file, Amgen; 2023.